HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target
10/15/2026
Impact: 85
Healthcare
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ: PRAX) and maintained a price target of $120.01. This recommendation reflects confidence in the company's performance and potential growth.
AI summary, not financial advice
Share: